TELA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
TELA is not a good buy right now for an impatient investor. The broader trend is still bearish (downtrend moving-average stack), recent earnings/guidance were disappointing, and Wall Street price targets were cut materially. While there are early signs of stabilization (slightly positive/expanding MACD, RSI neutral) and options positioning is extremely call-skewed, there is no proprietary buy signal today and no clear catalyst. Best action now is to hold/avoid initiating a new position at ~$1.00–$1.02.
Trend/structure: Bearish moving averages (SMA_200 > SMA_20 > SMA_5) indicate the primary trend is still down despite the recent +2.95% regular-session bounce. Momentum: MACD histogram is positive (0.00139) and expanding, suggesting a tentative momentum turn upward, but it has not yet overcome the bearish trend structure. RSI(6)=53.78 is neutral—no oversold snapback signal and no strong overbought pressure. Levels: Pivot 0.976 is the near-term decision point; post-market ~1.02 is above pivot and testing resistance. Immediate resistances: R1 1.016 (already being tested) and R2 1.041 (next upside checkpoint). Supports: S1 0.936 then S2 0.912. Practical read: price is pressing into resistance while still in a larger downtrend—risk of rejection remains elevated unless it can build acceptance above ~1.04.
Q3 2025 revenue grew +9.14% YoY to 20.689M, showing top-line growth.
Early technical improvement: MACD has turned positive and is expanding.
Options positioning is heavily call-leaning (sentiment tailwind).
Hedge funds and insiders show neutral activity (no fresh bearish flow flagged).
Guidance and execution concerns: recent quarter missed top-line expectations and full-year guidance was lowered (per analysts).
Profitability deterioration: Q3 2025 net loss widened (Net Income -8.603M, down -17.06% YoY) and EPS worsened to -0.19 (down -54.76% YoY).
Strong downtrend remains intact (SMA_200 > SMA_20 > SMA_5), meaning rallies can fade at resistance.
Analyst price targets were cut sharply, signaling reduced near-term confidence.
No news/catalyst in the past week to drive an immediate re-rating higher.
Latest quarter: 2025/Q3. Revenue increased to 20.689M (+9.14% YoY), but profitability weakened: Net Income fell to -8.603M (-17.06% YoY) and EPS fell to -0.19 (-54.76% YoY). Gross margin was 67.52%, slightly lower (-0.46% YoY). Bottom line: growth is present, but losses are widening, which aligns with the cautious post-earnings analyst resets.
Recent trend: ratings largely remain constructive (Buy/Outperform maintained by Canaccord and Citizens JMP), but price targets were cut meaningfully after a challenged Q3 and lowered guidance: Canaccord to $4 from $7; Citizens JMP to $5 from $7; Piper Sandler kept Neutral and cut PT to $1.25 from $2. Wall Street pros: belief in commercial strategy and salesforce build-out, plus international/customer adds. Wall Street cons: Q3 miss, lowered revenue guidance, and operating loss/EPS deterioration—leading to reduced targets and a more cautious near-term outlook. Influential/political flow: No recent congress trading data available; hedge fund and insider trend signals are neutral with no notable recent activity.
Intellectia Proprietary Trading Signals
